Nicola de'Angelis1, Filippo Landi2,3,4, Giulio Cesare Vitali5, Riccardo Memeo6, Aleix Martínez-Pérez2, Alejandro Solis3,4, Michela Assalino5, Francesc Vallribera3,4, Henry Alexis Mercoli6, Jacques Marescaux6, Didier Mutter6, Frédéric Ris5, Eloy Espin3,4, Francesco Brunetti2. 1. Unit of Digestive, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Henri Mondor Hospital, AP-HP, University of Paris Est, UPEC, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France. nic.deangelis@yahoo.it. 2. Unit of Digestive, Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Henri Mondor Hospital, AP-HP, University of Paris Est, UPEC, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France. 3. Unit of Colorectal Surgery, Department of General and Digestive Surgery, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 4. Universidad Autonoma de Barcelona, UAB, Barcelona, Spain. 5. Service of Abdominal Surgery, Geneva University Hospitals and Medical School, Geneva, Switzerland. 6. Department of Digestive Surgery, University Hospital of Strasbourg, 67091, Strasbourg, France.
Abstract
BACKGROUND: The use of laparoscopy for advanced-stage rectal cancer remains controversial. This study aimed to compare the operative and oncologic outcomes of laparoscopic (LAR) versus open anterior rectal resection (OAR) for patients with pT4 rectal cancer. METHODS: This is a multicenter propensity score matching (PSM) study of patients undergoing elective curative-intent LAR or OAR for pT4 rectal cancer (TNM stage II/III/IV) between 2005 and 2015. RESULTS: In total, 137 patients were included in the analysis. After PSM, demographic, clinical and tumor characteristics were similar between the 52 LAR and the 52 OAR patients. Overall, 52 tumors were located in the high rectum, 25 in the mid-rectum and 27 in the low rectum. Multivisceral resection was performed in 26.9% of LAR and 30.8% of OAR patients (p = 0.829). Conversion was required in 11 LAR patients (21.2%). The LAR group showed significantly shorter time to flatus (3.13 vs. 4.97 days, p = 0.001), time to regular diet (3.59 vs. 6.36 days, p < 0.0001) and hospital stay (15.49 vs. 17.96 days, p = 0.002) compared to the OAR group. The 90-day morbidity and mortality were not different between groups. In the majority of patients (85.6%), R0 resection was achieved. A complete mesorectal excision was obtained in 82.7% of LAR and 78.8% of OAR patients (p = 0.855). The 1-, 2- and 3-year overall survival rates were, respectively, 95.6, 73.8 and 66.7% for the LAR group and 86.7, 66.9 and 64.1% for the OAR group (p = 0.219). The presence of synchronous metastases (hazard ratio 2.26), R1 resection (HR 2.71) and lymph node involvement (HR 2.24) were significant predictors of overall survival. CONCLUSION: The present study suggests that LAR for pT4 rectal cancer can achieve good pathologic and oncologic outcomes similar to open surgery despite the risk of conversion. Moreover, laparoscopy offers the benefits of a faster recovery and a shorter hospital stay.
BACKGROUND: The use of laparoscopy for advanced-stage rectal cancer remains controversial. This study aimed to compare the operative and oncologic outcomes of laparoscopic (LAR) versus open anterior rectal resection (OAR) for patients with pT4 rectal cancer. METHODS: This is a multicenter propensity score matching (PSM) study of patients undergoing elective curative-intent LAR or OAR for pT4 rectal cancer (TNM stage II/III/IV) between 2005 and 2015. RESULTS: In total, 137 patients were included in the analysis. After PSM, demographic, clinical and tumor characteristics were similar between the 52 LAR and the 52 OAR patients. Overall, 52 tumors were located in the high rectum, 25 in the mid-rectum and 27 in the low rectum. Multivisceral resection was performed in 26.9% of LAR and 30.8% of OAR patients (p = 0.829). Conversion was required in 11 LAR patients (21.2%). The LAR group showed significantly shorter time to flatus (3.13 vs. 4.97 days, p = 0.001), time to regular diet (3.59 vs. 6.36 days, p < 0.0001) and hospital stay (15.49 vs. 17.96 days, p = 0.002) compared to the OAR group. The 90-day morbidity and mortality were not different between groups. In the majority of patients (85.6%), R0 resection was achieved. A complete mesorectal excision was obtained in 82.7% of LAR and 78.8% of OAR patients (p = 0.855). The 1-, 2- and 3-year overall survival rates were, respectively, 95.6, 73.8 and 66.7% for the LAR group and 86.7, 66.9 and 64.1% for the OAR group (p = 0.219). The presence of synchronous metastases (hazard ratio 2.26), R1 resection (HR 2.71) and lymph node involvement (HR 2.24) were significant predictors of overall survival. CONCLUSION: The present study suggests that LAR for pT4 rectal cancer can achieve good pathologic and oncologic outcomes similar to open surgery despite the risk of conversion. Moreover, laparoscopy offers the benefits of a faster recovery and a shorter hospital stay.
Entities:
Keywords:
Laparoscopy; Locally advanced rectal cancer; Open surgery; Propensity score matching; Radiochemotherapy; Rectal cancer
Authors: E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde Journal: N Engl J Med Date: 2001-08-30 Impact factor: 91.245
Authors: Pierre J Guillou; Philip Quirke; Helen Thorpe; Joanne Walker; David G Jayne; Adrian M H Smith; Richard M Heath; Julia M Brown Journal: Lancet Date: 2005 May 14-20 Impact factor: 79.321
Authors: Daniel P Nussbaum; Paul J Speicher; Asvin M Ganapathi; Brian R Englum; Jeffrey E Keenan; Christopher R Mantyh; John Migaly Journal: J Gastrointest Surg Date: 2014-08-05 Impact factor: 3.452
Authors: M Kusters; C A M Marijnen; C J H van de Velde; H J T Rutten; M J Lahaye; J H Kim; R G H Beets-Tan; G L Beets Journal: Eur J Surg Oncol Date: 2010-01-21 Impact factor: 4.424
Authors: H Hino; T Yamaguchi; Y Kinugasa; A Shiomi; H Kagawa; Y Yamakawa; M Numata; A Furutani; Y Yamaoka; S Manabe; T Suzuki; S Kato Journal: Tech Coloproctol Date: 2017-11-13 Impact factor: 3.781
Authors: Rogier M P H Crolla; Janneke J C Tersteeg; George P van der Schelling; Jan H Wijsman; Jennifer M J Schreinemakers Journal: Surg Endosc Date: 2018-05-16 Impact factor: 4.584
Authors: Mateusz Rubinkiewicz; Michał Nowakowski; Mateusz Wierdak; Magdalena Mizera; Marcin Dembiński; Magdalena Pisarska; Piotr Major; Piotr Małczak; Andrzej Budzyński; Michał Pędziwiatr Journal: Cancer Manag Res Date: 2018-11-01 Impact factor: 3.989
Authors: Marco Milone; Michele Manigrasso; Morena Burati; Nunzio Velotti; Francesco Milone; Giovanni Domenico De Palma Journal: PLoS One Date: 2018-10-09 Impact factor: 3.240